Edesa Biotech: Stonepine reports 30,000 shares (0.3%)

Edesa Biotech, Inc. ownership update: Stonepine entities and Jon M. Plexico report beneficial ownership of 30,000 shares of Common Stock, representing 0.3% of the class.

Accepted by SEC EDGAR 05/15/2026 - 05:15 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Edesa Biotech, Inc. ownership update: Stonepine entities and Jon M. Plexico report beneficial ownership of 30,000 shares of Common Stock, representing 0.3% of the class.

The filing states the percentage is calculated based on 8,891,951 shares outstanding as of May 13, 2026. The reporting persons say the shares were not acquired to influence control and disclaim group membership.

Insights

Institutional Ownership Analyst

Minor passive stake reported by Stonepine and affiliated persons.

The filing shows the Partnership, its general partner and Mr. Plexico each report shared voting and dispositive power over 30,000 shares, equal to 0.3% of outstanding common stock as of May 13, 2026. This positions them below common 5% reporting thresholds.

Cash‑flow treatment and acquisition timing are not stated in the excerpt; subsequent filings could clarify intent or any changes in position.

Governance & Compliance Specialist

Disclosure emphasizes disclaimers and non‑group filing.

The report includes standard disclaimers: the reporting persons disclaim group status and beneficial ownership beyond pecuniary interest and certify shares were not acquired to change control. The filing references an executed joint filing agreement (Exhibit 99).

Investors seeking governance impact should note the 0.3% stake is routine and below thresholds that typically trigger control concerns.

Key Figures

Reported shares: 30,000 shares Percent of class: 0.3% Shares outstanding used: 8,891,951 shares

3 metrics

Reported shares 30,000 shares Beneficial ownership reported by Stonepine and affiliates

Percent of class 0.3% Calculated using 8,891,951 shares outstanding as of May 13, 2026

Shares outstanding used 8,891,951 shares Basis for percentage calculation as reported from Form 10-Q for quarter ended March 31, 2026

Key Terms

Beneficial ownership, Shared dispositive power, Schedule 13G/A, Joint Filing Agreement

4 terms

Beneficial ownership regulatory

"Amount beneficially owned: Stonepine: 30,000 Partnership: 30,000"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Shared dispositive power regulatory

"Shared Dispositive Power 30,000.00 for Stonepine and affiliates"

Schedule 13G/A regulatory

"(Amendment No. 1 ) Edesa Biotech, Inc. Common Stock 27966L306"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

Joint Filing Agreement legal

"Exhibit 99 - Agreement Regarding Joint Filing of Statement on Schedule 13D or 13G"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Stonepine report in Edesa Biotech (EDSA)?

Stonepine reports beneficial ownership of 30,000 shares, equal to 0.3% of common stock. The percentage uses 8,891,951 shares outstanding as of May 13, 2026 per the issuer's Form 10-Q.

Who are the reporting persons on the Schedule 13G/A for EDSA?

The filing is by Stonepine Capital Management, LLC, Stonepine Capital, L.P., Stonepine GP, LLC, and Jon M. Plexico. Mr. Plexico is identified as the control person of Stonepine and the General Partner.

Does the filing indicate an intent to influence control of Edesa Biotech?

No. The signatory certifies the securities were not acquired and are not held to change or influence control. The reporting persons also disclaim membership in a group in this filing.

How is voting and dispositive power allocated for the reported shares?

Each reporting person lists 0 sole voting/dispositive power and 30,000 shared voting and shared dispositive power over the shares, as shown in the ownership table on the cover sheet.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Edesa Biotech, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

27966L306

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 27966L306

1

Names of Reporting Persons

Stonepine Capital Management, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 30,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 30,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

30,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.3 %

12

Type of Reporting Person (See Instructions)

IA, OO

Comment for Type of Reporting Person: Percentage calculated based on 8,891,951 shares of Common Stock outstanding as of May 13, 2026, as reported in the Form 10-Q filed by the Issuer for the quarter ended March 31, 2026.

SCHEDULE 13G

CUSIP Number(s): 27966L306

1

Names of Reporting Persons

Stonepine Capital, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 30,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 30,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

30,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.3 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: Percentage calculated based on 8,891,951 shares of Common Stock outstanding as of May 13, 2026, as reported in the Form 10-Q filed by the Issuer for the quarter ended March 31, 2026.

SCHEDULE 13G

CUSIP Number(s): 27966L306

1

Names of Reporting Persons

Stonepine GP, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 30,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 30,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

30,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.3 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: Percentage calculated based on 8,891,951 shares of Common Stock outstanding as of May 13, 2026, as reported in the Form 10-Q filed by the Issuer for the quarter ended March 31, 2026.

SCHEDULE 13G

CUSIP Number(s): 27966L306

1

Names of Reporting Persons

Jon M. Plexico

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 30,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 30,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

30,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.3 %

12

Type of Reporting Person (See Instructions)

HC, IN

Comment for Type of Reporting Person: Percentage calculated based on 8,891,951 shares of Common Stock outstanding as of May 13, 2026, as reported in the Form 10-Q filed by the Issuer for the quarter ended March 31, 2026.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Edesa Biotech, Inc.
(b)	Address of issuer's principal executive offices: 100 Spy Court, Markham, ON, Canada L3R 5H6
Item 2.
(a)	Name of person filing: Stonepine Capital Management, LLC, a Delaware limited liability company ("Stonepine") Stonepine Capital, L.P., a Delaware limited partnership (the "Partnership") Stonepine GP, LLC, a Delaware limited liability company (the "General Partner") Jon M. Plexico Stonepine and the General Partner are the investment adviser and general partner, respectively, of the Partnership. Mr. Plexico is the control person of Stonepine and the General Partner. The reporting persons are filing this Schedule 13G jointly, but not as members of a group, and each disclaims membership in a group. Each reporting person also disclaims beneficial ownership of Common Stock except to the extent of that person's pecuniary interest therein. In addition, the filing of this Schedule 13G on behalf of the Partnership should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any Common Stock covered by this Schedule 13G.
(b)	Address or principal business office or, if none, residence: 919 NW Bond Street, Suite 204 Bend, OR 97703
(c)	Citizenship: See Item 4 of the cover sheet for each reporting person.
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 27966L306
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Stonepine: 30,000 Partnership: 30,000 General Partner: 30,000 Jon M. Plexico: 30,000
(b)	Percent of class: Stonepine: 0.3% Partnership: 0.3% General Partner: 0.3% Jon M. Plexico: 0.3%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Stonepine: 0 Partnership: 0 General Partner: 0 Jon M. Plexico: 0
	(ii) Shared power to vote or to direct the vote: Stonepine: 30,000 Partnership: 30,000 General Partner: 30,000 Jon M. Plexico: 30,000
	(iii) Sole power to dispose or to direct the disposition of: Stonepine: 0 Partnership: 0 General Partner: 0 Jon M. Plexico: 0
	(iv) Shared power to dispose or to direct the disposition of: Stonepine: 30,000 Partnership: 30,000 General Partner: 30,000 Jon M. Plexico: 30,000
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The Partnership holds Common Stock for the benefit of its investors and has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, Common Stock.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Stonepine Capital Management, LLC

Signature:	/s/ Jon M. Plexico
Name/Title:	Managing Member
Date:	05/15/2025

Stonepine Capital, L.P.

Signature:	/s/ Jon M. Plexico
Name/Title:	Managing Member of the General Partner, Stonepine GP, LLC
Date:	05/15/2025

Stonepine GP, LLC

Signature:	/s/ Jon M. Plexico
Name/Title:	Managing Member
Date:	05/15/2025

Jon M. Plexico

Signature:	/s/ Jon M. Plexico
Name/Title:	Reporting person
Date:	05/15/2025

Exhibit Information

Exhibit 99 - Agreement Regarding Joint Filing of Statement on Schedule 13D or 13G